Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests

Executive Summary

During update on user fee discussions with industry to support FDA's OTC monograph program work, CDER officials say "industry and public would suffer" absent new fees.

Advertisement

Related Content

Second Wind For OTC Monograph User Fees Legislation In House Hearing
OTC Monograph User Fees Totaling $22m To $34m Floated In Senate Discussion Draft
FDA Rule Marks Consumer Antibac Soaps A Possible Endangered Species
OTC Monograph User Fees: FDA-Industry Talks Move From Basics To Details
'Real Appetite' For User Fees Among Energy & Commerce Democrats
FDA May Well Need OTC Drug Funding, But Stakeholders Want Program Specifics
Rulemaking Process Flawed, But Making Monograph Rules Still Needs Funding
PCPC: Cosmetic Legislation A Long Shot In 2016, But Objectives Are Clear
Sunscreen TEA Advocates Want Help Scaling FDA’s ‘High Bar’ For OTC Monographs
“No End In Sight” For Completing OTC Monographs – CDER Director Woodcock

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS119090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel